Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma: Results of two phase II clinical trials
dc.contributor.author | Bacoyiannis, Charalambos | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Samelis, G. | en |
dc.contributor.author | Onienaoum, A. | en |
dc.contributor.author | Kiamouris, Ch | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Triantafillidis, A. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.creator | Bacoyiannis, Charalambos | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Samelis, G. | en |
dc.creator | Onienaoum, A. | en |
dc.creator | Kiamouris, Ch | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Triantafillidis, A. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.date.accessioned | 2018-06-22T09:52:29Z | |
dc.date.available | 2018-06-22T09:52:29Z | |
dc.date.issued | 2002 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41375 | |
dc.description.abstract | Background: The aim of this study is firstly to determine the response rates and toxicity of two regimens containing vinblastine (VBL) in combination with interferon-gamma (IFN-γ) in the treatment of patients with advanced renal cell carcinoma (RCC), and secondly to evaluate the additional efficacy of 13-cis retinoic acid (13-CRA) in RCC. Methods: Twenty-nine patients were included in the first trial (Trial 1) and 40 in the second one (Trial 2). The therapy given in Trial 1 consisted of VBL 0.15 mg/kg i.v. every 2 weeks and IFN-γ 100 μg s.c. 3 times weekly. In Trial 2, the therapy consisted of the same two drugs, in the same doses, plus oral 13-CRA 40 mg/day. Results: In Trial 1 there were 3 (10.3%) patients with complete response, 3 (10.3%) patients with partial response, 8 (27.6%) patients with stable disease and 15 (51.7%) patients with progressive disease. In Trial 2, there was no complete response, however, 3 (7.5%) patients had partial response. Additionally, 15 (37.5%) patients maintained stable disease and 14 (35%) patients had progressive disease. In Trial 1, the median survival was 12.56 months (95% CI, 6.8-18.3, range 0.59-42.49) and the median time to progression was 3.21 months (95% CI, 1.7-4.7, range 0.03-42.49). In Trial 2, the median survival was 9.54 months (95% CI, 5.9-13.1, range 0.43-24.1) and the median time to progression was 3.9 months (95% CI, 0.8-7, range 0.26-24.1). In Trial 1, granulocytopenia grade 3 and 4 appeared in 5 (17.2%) patients and anaemia grade 3 in 1 (3.4%) patient. In Trial 2, there were grade 3 toxicities, as granulocytopenia in 5 (12.5%) patients, anemia in 4 (10.0%) patients, stomatitis in 3 (7.5%) patients, fatigue/ malaise in 3 (7.5%) patients and 1 (2.5%) had diarrhea. No toxic deaths occurred in both studies. Conclusion: The use of IFN-γ does not enhance the low response of VBL-based chemotherapy. The additional administration of 13-CRA with the combination of VBL and IFN-γ does not add to the efficacy of this combination in patients with advanced renal cell carcinoma. New active agents are needed to treat patients with this disease. Copyright © 2002 S. Karger AG, Basel. | en |
dc.language.iso | eng | en |
dc.source | Oncology | en |
dc.subject | Article | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Disease progression | en |
dc.subject | Neoplasm staging | en |
dc.subject | Priority journal | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Disease-free survival | en |
dc.subject | Drug effect | en |
dc.subject | Fatigue | en |
dc.subject | Stomatitis | en |
dc.subject | Vinblastine | en |
dc.subject | Human tissue | en |
dc.subject | Survival analysis | en |
dc.subject | Time factors | en |
dc.subject | 13-cis retinoic acid | en |
dc.subject | Carcinoma | en |
dc.subject | Disease course | en |
dc.subject | Gamma interferon | en |
dc.subject | Granulocytopenia | en |
dc.subject | Interferon type ii | en |
dc.subject | Interferon-gamma | en |
dc.subject | Isotretinoin | en |
dc.subject | Kidney carcinoma | en |
dc.subject | Kidney neoplasms | en |
dc.subject | Malaise | en |
dc.subject | Male | en |
dc.subject | Renal cell | en |
dc.subject | Renal cell carcinoma | en |
dc.title | Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma: Results of two phase II clinical trials | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1159/000063806 | |
dc.description.volume | 63 | |
dc.description.issue | 2 | |
dc.description.startingpage | 130 | |
dc.description.endingpage | 138 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |